A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer

This study is a multicenter, open-label, randomized controlled Phase 3 clinical trial. It is planned to enroll 240 female patients with locally advanced or metastatic breast cancer followed by disease progression after previous endocrine therapy.

Trial Details

NCT ID

NCT07024173

Phase

PHASE3

Sponsor

Shandong Suncadia Medicine Co., Ltd.

Status

RECRUITING

Cancer Type

Breast Cancer

Interventions

HRS-8080 Tablet
Fulvestrant injection
Exemestane tablets
Everolimus Tablets
Anastrozole Tablets
Letrozole Tablets

Locations (sample)

Guangzhou, Guangdong, China|23.11667,113.25
Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

Women aged 18 to 75 years old (including both values).
ECOG Physical Strength Status (PS) : 0 to 1 point.
Patients with locally advanced or metastatic breast cancer confirmed by histology.
Patients previously received 1-2 lines of endocrine therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →